Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model

Akihiro Mouri, Yukihiro Noda, Hideo Hara, Hiroyuki Mizoguchi, Takeshi Tabira, Toshitaka Nabeshima

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Immunotherapy with Aβ is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying Aβ cDNA (AAV/Aβ). The vaccine reduces the amount of Aβ deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/Aβ to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased Aβ deposition, insoluble Aβ, soluble Aβ oligomer (Aβ*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/Aβ- vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/Aβ is a safe and effective treatment for AD.

Original languageEnglish
Pages (from-to)2135-2148
Number of pages14
JournalFASEB Journal
Volume21
Issue number9
DOIs
Publication statusPublished - 01-07-2007
Externally publishedYes

Fingerprint

oral vaccination
Memory Disorders
Infiltration
Alzheimer Disease
Vaccination
Alzheimer disease
Complementary DNA
inflammation
Inflammation
infiltration (hydrology)
Data storage equipment
Alzheimer Vaccines
Immunotherapy
immunotherapy
Brain
mice
Vaccines
testing
Object recognition
Hematoxylin

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

@article{c01e1d69877a468a8075ee27f37d6f66,
title = "Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model",
abstract = "Immunotherapy with Aβ is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying Aβ cDNA (AAV/Aβ). The vaccine reduces the amount of Aβ deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/Aβ to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased Aβ deposition, insoluble Aβ, soluble Aβ oligomer (Aβ*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/Aβ- vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/Aβ is a safe and effective treatment for AD.",
author = "Akihiro Mouri and Yukihiro Noda and Hideo Hara and Hiroyuki Mizoguchi and Takeshi Tabira and Toshitaka Nabeshima",
year = "2007",
month = "7",
day = "1",
doi = "10.1096/fj.06-7685com",
language = "English",
volume = "21",
pages = "2135--2148",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. / Mouri, Akihiro; Noda, Yukihiro; Hara, Hideo; Mizoguchi, Hiroyuki; Tabira, Takeshi; Nabeshima, Toshitaka.

In: FASEB Journal, Vol. 21, No. 9, 01.07.2007, p. 2135-2148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model

AU - Mouri, Akihiro

AU - Noda, Yukihiro

AU - Hara, Hideo

AU - Mizoguchi, Hiroyuki

AU - Tabira, Takeshi

AU - Nabeshima, Toshitaka

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Immunotherapy with Aβ is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying Aβ cDNA (AAV/Aβ). The vaccine reduces the amount of Aβ deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/Aβ to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased Aβ deposition, insoluble Aβ, soluble Aβ oligomer (Aβ*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/Aβ- vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/Aβ is a safe and effective treatment for AD.

AB - Immunotherapy with Aβ is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying Aβ cDNA (AAV/Aβ). The vaccine reduces the amount of Aβ deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/Aβ to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased Aβ deposition, insoluble Aβ, soluble Aβ oligomer (Aβ*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/Aβ- vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/Aβ is a safe and effective treatment for AD.

UR - http://www.scopus.com/inward/record.url?scp=34347399599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347399599&partnerID=8YFLogxK

U2 - 10.1096/fj.06-7685com

DO - 10.1096/fj.06-7685com

M3 - Article

C2 - 17341681

AN - SCOPUS:34347399599

VL - 21

SP - 2135

EP - 2148

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -